abstract |
Provided herein is a method of treating cancer characterized by a high frequency of one or more inhibitory immune cells, comprising administering a therapeutically effective amount of enhancer of zestomolog2 (EZH2) inhibitor. A method is provided. In addition, a combination therapy using an EZH2 inhibitor and a second agent that is an immunomodulator is provided. [Selection] Figure 1 |